Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls

References

• Frazer R, Irvine AE, McMullin MF. Chronic myeloid leukaemia in the 21st century. Ulster Med J. 2007;76(1):8–17.
   PubMedGoogle Scholar
• Omunakwe HE, Nwauche CA, Kaladada KI. Chronic Myeloid Leukemia: clinical and laboratory features at presentation to a referral hospital in Southern Nigeria. Blood. 2013;122(21):5174. doi:10.1182/blood.V122.21.5174.5174
   Web of Science ®Google Scholar
• Sanyaolu AA, Yemisi BA, Muheez AD, Akeem OL. Otological diseases in patients with chronic Myeloid Leukemia. J Leukemia. 2014;2(128):1–3.
   Google Scholar
• O’Brien S, Berman E, Moore JO, et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Cancer Netw. 2011;9(Suppl 2):S-1-S-25.
   PubMedGoogle Scholar
• Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138–5144. doi:10.1182/blood-2013-01-480194
   PubMed Web of Science ®Google Scholar
• Lang K, McGarry LJ, Huang H, Dorer D, Kaufman E, Knopf K. Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-medicare data. Clin Lymphoma Myeloma Leuk. 2016;16(5):275–285.e271. doi:10.1016/j.clml.2016.01.006
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Eng J Med. 2003;348(11):994–1004. doi:10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Saif MW, Khan U, Greenberg BR. Cardiovascular manifestations of myeloproliferative disorders: a review of the literature. Hosp Phy. 1999;23:43–54.
   Google Scholar
• Kadikoylu G, Onbasili A, Tekten T, Barutca S, Bolaman Z. Functional and morphological cardiac changes in myeloproliferative disorders (clinical study). Int J Cardiol. 2004;97(2):213–220. doi:10.1016/j.ijcard.2003.08.013
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302. doi:10.1182/blood-2002-04-1199
   PubMed Web of Science ®Google Scholar
• Henry WL, DeMaria A, Gramiak R, et al. Report of the American Society of Echocardiography Committee on nomenclature and standards in two-dimensional Echocardiography. Circulation. 1980;62(2):212–217. doi:10.1161/01.CIR.62.2.212
   PubMed Web of Science ®Google Scholar
• Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58(6):1072–1083. doi:10.1161/01.CIR.58.6.1072
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–458. doi:10.1016/0002-9149(86)90771-X
   PubMed Web of Science ®Google Scholar
• Ajayi OE, Ajayi EA, Akintomide OA, et al. Ambulatory blood pressure profile and left ventricular geometry in Nigerian hypertensives. J Cardiovasc Dis Res. 2011;2(3):164–171. doi:10.4103/0975-3583.85263
   PubMedGoogle Scholar
• Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;59(9):956–960. doi:10.1016/0002-9149(87)91133-7
   PubMed Web of Science ®Google Scholar
• Diaz RA, Obasohan A, Oakley CM. Prediction of outcome in dilated cardiomyopathy. Br Heart J. 1987;58(4):393–399. doi:10.1136/hrt.58.4.393
   PubMedGoogle Scholar
• Wiegers SE. Diastolic echo parameters: meaningless numbers or crucial information? Circ Cardiovasc Imaging. 2011;4(5):460–462. doi:10.1161/CIRCIMAGING.111.968131
   PubMed Web of Science ®Google Scholar
• Bukachi F, Waldenström A, Mörner S, Lindqvist P, Henein MY, Kazzam E. Pulmonary venous flow reversal and its relationship to atrial mechanical function in normal subjects – Umeå General Population Heart Study. Eur Heart J Cardiovasc Imaging. 2005;6(2):107–116.
   Google Scholar
• Akintunde AA. The clinical value of the Tei index among Nigerians with hypertensive heart failure: correlation with other conventional indices: cardiovascular topics. Cardiovasc J Afr. 2012;23(1):40–43. doi:10.5830/CVJA-2011-032
   PubMed Web of Science ®Google Scholar
• Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function–a study in normals and dilated cardiomyopathy. J Cardiol. 1995;26(6):357–366.
   PubMedGoogle Scholar
• Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009;30(20):2493–2537. doi:10.1093/eurheartj/ehp297
   PubMed Web of Science ®Google Scholar
• Chemla D, Castelain V, Humbert M, et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. CHEST J. 2004;126(4):1313–1317. doi:10.1378/chest.126.4.1313
   PubMed Web of Science ®Google Scholar
• Sciomer S, Magrì D, Badagliacca R. Non-invasive assessment of pulmonary hypertension: Doppler–echocardiography. Pulm Pharmacol Ther. 2007;20(2):135–140. doi:10.1016/j.pupt.2006.03.008
   PubMed Web of Science ®Google Scholar
• Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography: endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713. doi:10.1016/j.echo.2010.05.010
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–1619. doi:10.1016/j.jacc.2009.01.004
   PubMed Web of Science ®Google Scholar
• Karaye KM, Saidu H, Bala MS, Yahaya IA. Prevalence, clinical characteristics and outcome of pulmonary hypertension among admitted heart failure patients. Ann Afr Med. 2013;12(4):197–204. doi:10.4103/1596-3519.122685
   PubMedGoogle Scholar
• Fleming AF. Epidemiology of the leukaemias in Africa. Leuk Res. 1979;3(2):51–59. doi:10.1016/0145-2126(79)90062-6
   PubMed Web of Science ®Google Scholar
• Okany CC, Akinyanju OO. Chronic leukaemia: an African experience. Med Oncol Tumor Pharmacother. 1989;6(3):189–194. doi:10.1007/BF02985189
   PubMedGoogle Scholar
• Boma PO, Durosinmi MA, Adediran IA, Akinola NO, Salawu L. Clinical and prognostic features of Nigerians with chronic myeloid leukemia. Niger Postgrad Med J. 2006;13(1):47–52.
   PubMedGoogle Scholar
• Williams O, Bamgboye E. Estimation of incidence of human leukaemia subtypes in an urban African population. Oncology. 1983;40(6):381–386. doi:10.1159/000225769
   PubMed Web of Science ®Google Scholar
• Omoti CE, Imiere EO. Trends in the pattern of leukaemia incidence in a tertiary health center in Nigeria: 1990–2004. J Biomed Sci. 2006;5(2):44–94.
   Google Scholar
• Louw VJ. Chronic myeloid leukaemia in South Africa. Hematology. 2012;17(sup1):S75–S78. doi:10.1179/102453312X13336169155817
   PubMed Web of Science ®Google Scholar
• Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013;37(3):247–254. doi:10.1016/j.canep.2013.01.002
   PubMed Web of Science ®Google Scholar
• Oyekunle AA, Bolarinwa RA, Oyelese AT, Salawu L, Durosinmi MA. Determinants of overall and progression-free survival of Nigerian patients with Philadelphia-positive chronic Myeloid Leukemia. Adv Hematol. 2015;2015:1–5. doi:10.1155/2015/908708
   Google Scholar
• Durosinmi MA, Faluyi JO, Oyekunle AA, et al. The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia. Cell Ther Transplant. 2008;1(2):58–62.
   Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi:10.1182/blood-2013-05-501569
   PubMed Web of Science ®Google Scholar
• Breccia M, Colafigli G, Molica M, Alimena G. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100–101. doi:10.1002/ajh.23976
   PubMed Web of Science ®Google Scholar
• Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100(1):116–121. doi:10.1002/cncr.11863
   PubMed Web of Science ®Google Scholar
• Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma. 2003;44(7):1239–1241. doi:10.1080/1042819031000079140
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Marcolino MS, Bittencourt HN, et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008;32(12):1809–1814. doi:10.1016/j.leukres.2008.03.020
   PubMed Web of Science ®Google Scholar
• Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15(suppl 3):14–18. doi:10.1093/oxfordjournals.ndt.a027970
   PubMed Web of Science ®Google Scholar
• Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279(3):217–221. doi:10.1001/jama.279.3.217
   PubMed Web of Science ®Google Scholar
• Cassis N, Porterfield J, Rogers JS, Shah S, Storey E. Massive hemopericardium as the initial manifestation of chronic myelogenous leukemia. Arch Intern Med. 1982;142(12):2193–2194. doi:10.1001/archinte.1982.00340250159025
   PubMedGoogle Scholar
• Quintás-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908–3914. doi:10.1200/JCO.2007.12.0329
   PubMed Web of Science ®Google Scholar
• Huang C-T, Yu S-H, Chen Y-H, Lin S-F. Cardiac tamponade as a symptom of the blast crisis of chronic myeloid leukemia. Kaohsiung J Med Sci. 2016;32(3):160–161. doi:10.1016/j.kjms.2016.02.007
   PubMed Web of Science ®Google Scholar
• Hammoud D, Shaheen M, Nassar R. Imatinib (Gleevec) induced worsening of pericardial effusion in CML. Firat Tip Dergisi. 2011;16(2):100–101.
   Google Scholar
• Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlogl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96(1):163–166. doi:10.3324/haematol.2010.030494
   PubMed Web of Science ®Google Scholar
• Bossone E, D’Andrea A, D’Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. 2013;26(1):1–14. doi:10.1016/j.echo.2012.10.009
   PubMed Web of Science ®Google Scholar
• Rossi M, Carillo S. Pathogenesis of cardiac hypertrophy in iron deficiency anaemia: the role of noradrenaline. Br J Exp Pathol. 1982;63(3):269.
   PubMedGoogle Scholar
• Kerkela R, Force T. Recent insights into cardiac hypertrophy and left ventricular remodeling. Curr Heart Fail Rep. 2006;3(1):14–18. doi:10.1007/s11897-006-0026-6
   PubMedGoogle Scholar
• O’Riordan E, Foley RN. Effects of anaemia on cardiovascular status. Nephrol Dial Transplant. 2000;15(suppl_3):19–22. doi:10.1093/oxfordjournals.ndt.a027971
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–916. doi:10.1038/nm1446
   PubMed Web of Science ®Google Scholar
• Khan MA. Effects of myotoxins on skeletal muscle fibers. Prog Neurobiol. 1995;46(5):541–560. doi:10.1016/0301-0082(95)00015-N
   PubMed Web of Science ®Google Scholar
• Atallah E, Durand J-B, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–1237. doi:10.1182/blood-2007-01-070144
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Medeot M. Cardiotoxicity of imatinib: at the heart of the problem. Leuk Res. 2011;35(1):36–37. doi:10.1016/j.leukres.2010.09.021
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173–1179. doi:10.3324/haematol.11420
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O’brien S, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–1061. doi:10.1038/leu.2009.38
   PubMed Web of Science ®Google Scholar
• Breccia M, Cannella L, Frustaci A, Stefanizzi C, Levi A, Alimena G. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience. Leuk Res. 2008;32(5):835–836. doi:10.1016/j.leukres.2007.08.016
   PubMed Web of Science ®Google Scholar
• Estabragh ZR, Knight K, Watmough SJ, et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res. 2011;35(1):49–51. doi:10.1016/j.leukres.2010.08.020
   PubMed Web of Science ®Google Scholar
• Hassan HH, Alawad AS, Murad NS. Echocardiographic evaluation of cardiac involvement in myeloproliferative disorders. Med J Babylon. 2008;5(3–4):556–574.
   Google Scholar
• Reisner SA, Rinkevich D, Markiewicz W, Tatarsky I, Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med. 1992;93(5):498–504. doi:10.1016/0002-9343(92)90576-W
   PubMed Web of Science ®Google Scholar
• Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis. Haematologica. 2001;86(12):1236–1244.
   PubMed Web of Science ®Google Scholar
• Tigen K, Karaahmet T, Kirma C, et al. The association of functional mitral regurgitation and anemia in patients with non-ischemic dilated cardiomyopathy. Cardiol J. 2010;17(3):274–280.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib access in clinical trials (ENACT). Cancer. 2012;118(1):118–126. doi:10.1002/cncr.26249
   PubMed Web of Science ®Google Scholar
• Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2010;117(8):e75–87. doi:10.1182/blood-2010-07-294330
   PubMed Web of Science ®Google Scholar